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Abstract
Background: The digitization of healthcare data, resulting from the increasingly widespread adoption of electronic
health records, has greatly facilitated its analysis by computational methods and thereby enabled large-scale secondary
use thereof. This can be exploited to support public health activities such as pharmacovigilance, wherein the safety of
drugs is monitored to inform regulatory decisions about sustained use. To that end, electronic health records have
emerged as a potentially valuable data source, providing access to longitudinal observations of patient treatment and
drug use. A nascent line of research concerns predictive modeling of healthcare data for the automatic detection of
adverse drug events, which presents its own set of challenges: it is not yet clear how to represent the heterogeneous
data types in a manner conducive to learning high-performing machine learning models.
Methods: Datasets from an electronic health record database are used for learning predictive models with the
purpose of detecting adverse drug events. The use and representation of two data types, as well as their
combination, are studied: clinical codes, describing prescribed drugs and assigned diagnoses, and measurements.
Feature selection is conducted on the various types of data to reduce dimensionality and sparsity, while allowing
for an in-depth feature analysis of the usefulness of each data type and representation.
Results: Within each data type, combining multiple representations yields better predictive performance compared
to using any single representation. The use of clinical codes for adverse drug event detection significantly
outperforms the use of measurements; however, there is no significant difference over datasets between using
only clinical codes and their combination with measurements. For certain adverse drug events, the combination
does, however, outperform using only clinical codes. Feature selection leads to increased predictive performance
for both data types, in isolation and combined.
Conclusions: We have demonstrated how machine learning can be applied to electronic health records for the
purpose of detecting adverse drug events and proposed solutions to some of the challenges this presents,
including how to represent the various data types. Overall, clinical codes are more useful than measurements and,
in specific cases, it is beneficial to combine the two.
Background
With the adoption of computerized medication ordering
and administration systems, the veil on the incidence of
adverse drug events (ADEs) is slowly being removed.
Unfortunately, ADEs are still considered to be heavily
under-reported [1]. Among the ADEs that are reported,
around half are preventable [2], causing unnecessary
suffering for patients and increased healthcare costs.
According to one meta-analysis, ADEs are, in fact,
responsible for around 4.9% of hospital admissions
worldwide, and, in some cases, this number can be as
high as 41.3% [3]. There is thus no doubt that drug
safety is an important public health problem. Unfortu-
nately, the high rate of ADEs may continue unabated
unless systems that provide decision support for drug
selection and dosing are developed and more widely
implemented at the point of care [4].
* Correspondence: jingzhao@dsv.su.se
Department of Computer and Systems Sciences, Stockholm University,
Borgarfjordsgatan 12, SE-16407 Kista, Sweden
Zhao et al. BMC Medical Informatics and Decision Making 2015, 15(Suppl 4):S1
http://www.biomedcentral.com/1472-6947/15/S4/S1
© 2015 Zhao et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://
creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Pharmacovigilance using electronic health records
Efforts have been made in pharmacovigilance to improve
drug safety. The World Health Organization (WHO)
defines pharmacovigilance as “the science and activities
relating to the detection, assessment, understanding and
prevention of adverse effects or any other drug-related
problem” [5]. The primary resources involved in pharma-
covigilance are clinical trials, spontaneous reports and
longitudinal healthcare databases [6]. The use of these can
be divided into pre-marketing and post-marketing phar-
macovigilance activities. In the pre-marketing stage, prior
to the launch of a drug, clinical trials are used to gather
information on both the efficacy and safety of a drug.
However, such a source of information comes with two
inherent limitations, namely small samples of participants
and short study duration. These limitations make it chal-
lenging to identify ADEs that are rare or occur with a long
latency. In the post-marketing stage, after the drug has
been launched, spontaneous reporting systems are used
continuously to collect information on the safety of the
drug. Examples of such systems are the US Food and
Drug Administration’s Adverse Event Reporting System
[7] and WHO’s Global Individual Case Safety Reports
Database, Vigibase [8]. Spontaneous reports are voluntarily
made by patients and physicians of suspected ADEs, which
allows for monitoring of all drugs on the market at a fairly
low cost. Unfortunately, such systems suffer heavily from
under-reporting: it has been estimated that more than
94% of ADEs are not reported through spontaneous
reports [9]. Other limitations of spontaneous reports
include selective reporting, incomplete patient information
and indeterminate population information; for more
details see [10]. Indeterminate population information is
particularly problematic since it prevents the calculation of
the incidence of reported ADEs. As a result of these lim-
itations, the need for alternative, complementary data
sources is duly being acknowledged.
Among the possible alternative data sources, which also
includes social media and medical literature, are electronic
health records (EHRs) [11] since they capture and inte-
grate patient data from all aspects of clinical observations
over time. Although the main function of EHRs is to
archive and manage patient data efficiently - in compari-
son to paper-based health record systems - secondary use
of EHR data is currently being widely explored for various
medical research, such as disease discovery and patient
stratification [12,13], among which also pharmacovigilance
has received a lot of attention. There are various ways of
utilizing EHRs for pharmacovigilance in a data-driven
fashion, such as calculating correlations between drugs
and diseases, clustering patients into different disease
groups, and employing machine learning based prediction
[14], among which the latter is particularly nascent.
Predictive modeling of data from electronic health records
Machine learning based methods are data-driven
approaches that can support discovery and exploitation
of statistical patterns from large quantities of data. Given
a large amount of observations that are described by mul-
tiple variables, such methods have proven to be robust to
random errors [15]. In areas where there is a need to ana-
lyze large amounts of data, such as bioinformatics,
machine learning is a key technique, particularly when
analyzing “big data” [16]. This is also the case in post-
marketing drug safety surveillance, where the discovery
process typically relies on large samples; computational
signal detection algorithms have in this context been
developed to analyze data with the purpose of detecting
signals of potential ADEs [17]. Some of these algorithms
detect signals according to a score function based on
contingency tables, such as disproportionality analysis of
spontaneous reports. However, a limitation of using con-
tingency tables is that, by reducing the analysis to only
two dimensions, the potential concomitant loss of clini-
cally crucial information may result in arbitrary associa-
tions [17,18]. This can be eschewed by instead employing
multivariate algorithms for signal detection, where
machine learning methods can provide efficient and
effective means of modeling high-dimensional data.
Applying machine learning to EHR data is, however,
challenging for various reasons. A natural way of fitting
EHR data into machine learning models is to utilize the
various clinical events that are recorded in EHRs as vari-
ables to describe, for instance, patients. For each patient,
these clinical events can be represented either as a
sequence according to reporting chronology, or as a bag,
in effect discarding order information. Treating clinical
events as sequences is, however, problematic for two rea-
sons: (1) many events have identical timestamps, which
raises the question of how to deal with simultaneously
occurring events; (2) there is a lack of understanding to
what extent the order of reported events reflects reality, i.
e., we cannot know whether the sequence of reported
events is the same as the actual sequence of events.
When representing clinical events as a bag, there are
other problems that need to be handled, as illustrated in
Figure 1. On the one hand, the data is often high-dimen-
sional and sparse, i.e., a large number of features describe
each patient, but many features have non-zero values
only for a small fraction of the patients. On the other
hand, the types of data available in EHRs are heteroge-
neous and complex. Typically, EHR data includes both
structured data according to predefined templates, such
as demographic patient information, drug prescriptions,
diagnoses, clinical measurements and lab tests, as well
unstructured data in the form of clinical notes written in
natural language. Moreover, for some types of data, such
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as prescribed drugs, assigned diagnoses and obtained
clinical measurements, a patient may have experienced
the same type of clinical event multiple times, for
instance a patient being prescribed a certain drug multi-
ple times. In summary, the challenges of analyzing EHR
data with machine learning methods stem not only from
high dimensionality and sparsity, but also from the exis-
tence of different data types that are tangled together
with missing and duplicated values.
Related work
Due to limited access to EHR data, research on exploit-
ing it for pharmacovigilance is still relatively scarce
compared to using other data sources, despite its
acknowledged potential. Among the published research
on using EHRs for ADE detection, some have focused
on using clinical notes [19-21], while how best to exploit
the structured data remains under-explored. In some
studies, however, clinical measurements or lab tests
from EHRs have been utilized for (adverse) event detec-
tion by representing them as time series [22], aggregat-
ing them into categorical variables [23], or representing
them from multiple perspectives [24]. Other studies
have used diagnoses and drugs instead [25,26], while
these data types have also been used in conjunction for
signaling ADEs, albeit only in a case study and on a
very limited scale [27].
Diagnoses and drugs are normally encoded by standard
coding systems such as International Statistical Classifi-
cation of Diseases and Related Health Problems (ICD)
and Anatomical Therapeutic Chemical Classification Sys-
tem (ATC), respectively. These coding systems have their
own concept hierarchies representing terms from general
levels to more specific ones according to organ system or
etiology. In a previous study, we have studied the possibi-
lity of exploiting these concept hierarchies to obtain
improved predictive performance on the task of distin-
guishing between patients who have experienced a speci-
fic ADE and randomly selected patients who have not
experienced that same ADE [26]. It was shown that for
such tasks, using only the more general levels of the
codes is sufficient to maintain the predictive performance
on a high level. We have also evaluated various ways of
representing clinical measurements from EHRs and dis-
covered that using such measurements alone still leads to
the effective detection of ADEs; moreover, using only the
Figure 1 Extracting data for machine learning methods from electronic health records.
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number of times each clinical measurement has been
taken, without considering their actual values, is a repre-
sentation that results in the highest predictive perfor-
mance for the most common learning algorithms [24].
However, previous studies have either used a single
data type from EHRs or a small number of pre-selected
variables from different data types to signal a specific
ADE. In this study, we explore if it is beneficial to com-
bine various data types, on a large scale, by using all of
the available variables for ADE detection, and also how
best to represent them. In addition to detecting specific
ADEs, this study aims to explore ways of using structured
EHR data that can be exploited to detect a wide range of
ADEs, which could be adopted in a general decision sup-
port system that alerts for potential ADEs.
Methods
In this study, we investigated the use of various data
types in EHRs for drug safety surveillance. Here, we
focused on using the structured data to build predictive
models using machine learning based methods. Clinical
measurements, diagnoses and drugs were extracted from
a real EHR database. Besides the known problems of
EHR data such as high dimensionality and sparsity,
these data types have their own characteristics and
hence lead to different challenges when fitting them
into predictive models. For example, some clinical
events here might be observed multiple times for one
patient, while some might not be observed at all. There-
fore, a series of experiments were conducted to explore
the use of these heterogeneous data types separately and
together when predicting ADEs with machine learning
based methods: first, different representations of each
data type were compared and the best representation of
the corresponding data type was selected for merging
with the other data types, i.e., to form a fused feature
set, which was compared to using each data type sepa-
rately; second, to reduce the high dimensionality and
sparsity, feature selection was conducted on both the
separate data types and the fused feature set, which also
allowed for an in-depth feature analysis; and finally, var-
ious commonly used learning algorithms were applied
and compared for the classification task.
Data source
Data was extracted from a Swedish EHR database, the
Stockholm EPR Corpus (this research has been approved
by the Regional Ethical Review Board in Stockholm with
permission number 2012/834-31/5). This database con-
tains health records of around 700,000 patients from 2009
to 2010, which were obtained from Karolinska University
Hospital in Stockholm, Sweden [28]. Here, large amounts
of diagnosis information, drug administrations, clinical
measurements, lab tests and clinical notes in free-text
from anonymized health records are available for research.
In this study, we only extracted the structured data, i.e.,
diagnoses, drugs and clinical measurements.
In the Stockholm EPR Corpus, diagnoses are encoded by
the International Statistical Classification of Diseases and
Related Health Problems, 10th Edition (ICD-10), some of
which indicate ADEs, e.g., G44.4 (drug-induced headache).
To create training data for building machine learning mod-
els, we used these ADE-related diagnosis codes as class
labels. The population is hence divided into patients that
have been assigned an ADE-related diagnosis code and
those who have not. In a study on the use of ICD-10 codes
for ADE reporting [29], the ADE-related diagnosis codes
were divided into categories according to the strength of
their indication for ADEs, where category A.1 (a drug-
related causation was noted in the diagnosis code) and
category A.2 (a drug-or other substance-related causation
was noted in the diagnosis code) were used in this study,
as they indicate the most certain causal drug-diagnosis
relationship of ADEs compared to the other categories.
To avoid spurious findings, we have selected 27 ADE-
related codes that are most frequently used in the Stock-
holm EPR Corpus, resulting in 27 datasets, where the exis-
tence of each ADE-related diagnosis code indicating a
particular ADE served as the class label in each dataset;
see Table 1 for the selected ADE-related diagnosis codes
and their description. The classification task is hence bin-
ary: positive or negative with respect to a specific ADE. In
each dataset, examples correspond to patients: patients
whom have been assigned an ADE-specific diagnosis code
constitute positive examples and patients whom have been
assigned a similar diagnosis code to the ADE-specific diag-
nosis code form negative examples, where two codes are
considered similar if they share the first three levels in the
concept hierarchy. For instance, if the positive examples
are patients with diagnosis code G44.4 (drug-induced
headache), the negative examples are patients with any
diagnosis code starting with G44 (other headache syn-
dromes), but not G44.4. Features are clinical events, i.e.,
diagnoses, drugs and clinical measurements, that are
reported in the health records of these patients prior to
the event of interest, i.e., the class label. The number of
instances, the proportion of the positive class and the
number of features from each data type for each dataset
are described in Table 2.
Experimental setup
The main underlying learning algorithm in this study is
random forest [30], which is an ensemble learning method
that generates a set of decision trees. Each tree in the for-
est is built with a bootstrapped sample from the original
training examples and each node in the tree only considers
a randomly selected subset of the original feature set. The
trees carry out the learning task independently from each
Zhao et al. BMC Medical Informatics and Decision Making 2015, 15(Suppl 4):S1
http://www.biomedcentral.com/1472-6947/15/S4/S1
Page 4 of 15
other and the forest eventually outputs the final result
through voting, i.e., averaging the output of all constituent
trees. The random forest learning algorithm has become
one of the most popular machine learning methods, espe-
cially in bioinformatics where data is often high dimen-
sional, as a result of its relatively low computational cost
and robust predictive performance [31].
Evaluation was done through 10-fold cross validation
with 10 iterations. The performance metrics used in this
study are accuracy and area under ROC curve (AUC).
Accuracy, the most common and perhaps also the most
intuitive metric to evaluate the performance of a predic-
tive model, measures the percentage of examples that
are predicted correctly. Area under ROC curve can be
used whenever the learning algorithm is able to rank
the examples based on the decreasing probability of pre-
dicting them as positive. It measures the probability of
ranking a true positive example ahead of a false positive
example [32], i.e., the rate of detecting true signals ver-
sus the false alarm rate. Compared to accuracy, AUC is
sometimes favored because it is not sensitive to changes
in the class distribution between training and test data.
When more than two models were compared, a Fried-
man test [33] was employed to test the statistical signifi-
cance, where the rank of each model is used. To look
further at the pairwise significance between the inspected
models, a post-hoc test using the Bergman-Hommel pro-
cedure was applied [34].
Using various data types
In the first experiment, different representations of clinical
measurements, on the one hand, and diagnoses and drugs
on the other (here we consider diagnoses and drugs as one
data type, namely clinical codes, as they share the same
characteristics), as well as their combination, were
compared.
Clinical measurements In a previous study [24], we
proposed five representations (listed below) of clinical
measurements to handle the problem that each measure-
ment can be observed multiple times for a patient. Here,
we re-evaluated the use of these representations, as well as
their combination, on a slightly different task.
• Mean - the average of the observed values
• SD - the standard deviation of the observed values
Table 1 The 27 selected ADE related diagnosis codes.
Code Description
D642 Secondary sideroblastic anemia due to drugs and toxins
E273 Drug-induced adrenocortical insufficiency
F110 Mental and behavioural disorders (MBDs) due to use of opioids: acute intoxication
F112 MBDs due to use of opioids: dependence syndrome
F130 MBDs due to use of sedatives or hypnotics: acute intoxication
F132 MBDs due to use of sedatives or hypnotics: dependence syndrome
F150 MBDs due to use of other stimulants, including caffeine: acute intoxication
F151 MBDs due to use of other stimulants, including caffeine: harmful use
F152 MBDs due to use of other stimulants, including caffeine: dependence syndrome
F190 MBDs due to multiple drug use: acute intoxication
F192 MBDs due to multiple drug use: dependence syndrome
F199 MBDs due to multiple drug use: unspecified mental and behavioural disorder
G240 Drug-induced dystonia
G251 Drug-induced tremor
G444 Drug-induced headache, not elsewhere classified
G620 Drug-induced polyneuropathy
I427 Cardiomyopathy due to drugs and other external agents
I952 Hypotension due to drugs
L270 Generalized skin eruption due to drugs and medicaments
L271 Localized skin eruption due to drugs and medicaments
O355 Maternal care for (suspected) damage to fetus by drugs
T782 Adverse effects: anaphylactic shock, unspecified
T783 Adverse effects: angioneurotic oedema
T784 Adverse effects: allergy, unspecified
T808 Other complications following infusion, transfusion and therapeutic injection
T886 Anaphylactic shock due to correct drug or medicament properly administered
T887 Unspecified adverse effect of drug or medicament
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• Slope - the difference between the first and last
observation over the time span
• Existence - whether or not a measurement has
been taken
• Count - the number of times a measurement was
taken
Clinical codes Diagnoses are encoded by the ICD-10
system and drugs by the ATC system in the Stockholm
EPR Corpus, both of which have inherent concept hier-
archies that can be used to aggregate the clinical codes
into different hierarchical levels, as shown in Figure 2.
Here, we compared using the different levels of clinical
codes to a combination of all levels.
After investigating representations of clinical measure-
ments and clinical codes separately, we combined them
using their respective best observed representation. As it
has previously been shown that, when an ensemble
model is employed, building the model from a fused set
of data types is favored compared to fusing ensemble
models built from the individual data type [35], we com-
bined the two data types by fusing them into one feature
set before applying the random forest algorithm. The
predictive performance of random forests using clinical
measurements, clinical codes and a combination of the
two were compared.
Feature selection
In a follow-up experiment, feature selection was added
to the pipeline prior to building the predictive models in
order to remove those features that are not informative,
while simultaneously reducing the dimensionality and,
in some cases, sparsity. There are two common types of
feature selection approaches: wrapper-based and filter-
based. The former utilizes the targeted learning algo-
rithm as a black box to evaluate the usefulness of
features according to their predictive performance [36],
while the latter selects features according to a score
function independent of the chosen learning algorithm
[37]. Wrapper-based approaches are generally consid-
ered to produce better feature subsets but with much
higher computational costs compared to the filter-based
approaches. In this study, we used a filter-based
approach to univariate feature selection, information
gain, to select relatively important features, where the
features are first ranked according to the information
gain between them and the class label before selecting
the top-ranked ones. The information gain for a certain
feature is calculated as the difference between the
entropy before splitting the training examples with this
feature and the entropy after splitting. The entropy of
the random variable x is
H (x) = −∑
x
p (x) log2p (x) ,
where p(x) is the probability distribution of x. In this
case, the entropy before splitting is the entropy by split-
ting the examples only according to the class label Y , H






Table 2 Statistical description of 27 datasets.
Number of features
Dataset Instances % Pos. Codes Measurements Combination
D642 3733 2.87% 3999 494 8262
E273 183 12% 912 240 2935
F110 146 22.6% 1051 205 2958
F112 146 63.7% 1054 205 2963
F130 112 54.5% 779 142 2237
F132 112 27.7% 777 142 2231
F150 111 14.4% 476 107 1543
F151 111 17.1% 475 107 1542
F152 111 69.4% 481 111 1573
F190 168 31.5% 869 160 2454
F192 168 50% 865 160 2447
F199 168 8.93% 866 160 2448
G240 68 20.6% 444 136 1636
G251 194 6.7% 1014 263 3209
G444 908 2.5% 1774 318 4594
G620 382 6% 1624 280 4152
I427 448 5.1% 1341 299 3852
I952 483 8.3% 1654 333 4471
L270 435 35.9% 1297 325 3912
L271 434 11.1% 1286 325 3897
O355 237 35.4% 736 110 1930
T782 1203 8.5% 1625 319 4405
T783 1207 8.6% 1627 319 4408
T784 1213 60.8% 1628 319 4409
T808 391 87.5% 1229 271 3533
T886 715 6.2% 2226 401 5606
T887 716 61.7% 2230 400 5604
Figure 2 Concept hierarchies of ATC and ICD-10 codes.
C10AA01 is the ATC code for Simvastatin and F25.1 is the ICD-10
code for Schizoaffective disorder.
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where, Yf is the probability distribution of the class
label given feature f. Therefore, the information gain of
feature f is
I(f ,Y) = H(Y) − H(Y|f ).
In this study, we explored the impact of feature selection
on the predictive performance of the random forest algo-
rithm with a set of thresholds starting from the top 10% of
available features ranked according to their information
gain scores and subsequently adding an extra 10% until
the full feature set is included.
Using various learning algorithms
The random forest algorithm is known for being robust
with high dimensional data; therefore, in the last experi-
ment, eight additional commonly used learning algo-
rithms were applied in order to find out if the
observation from using random forest holds for the
others and also to study the impact of feature selection
on this task. The selected learning algorithms and their
parameters are listed in Table 3. Each learning algo-
rithm used clinical measurements and clinical codes, in
isolation and combined, to build predictive models with
features selected on all thresholds.
Results
In this section, we report on the predictive performance,
in terms of accuracy and AUC, of models generated
with the random forest algorithm that was provided
with various representations of 27 clinical datasets, each
one containing a different data type (clinical codes and
measurements) and representation, as well as combina-
tions of these - with and without feature selection. We
present both results from individual datasets, as well as
summary results, averaged over datasets. An in-depth
feature analysis is moreover conducted and, finally,
results from using various learning algorithms are
summarized.
Using various data types
The clinical measurements were represented in five dis-
tinct ways - Mean, SD, Slope, Existence and Count - as
well as a combination of these. Accuracy and AUC,
averaged over 27 datasets, as obtained by random forest
models with access to the each of the representations
are presented in Table 4. For both accuracy and AUC,
using the combined representation yielded the best per-
formance. The clinical codes, on the other hand, were
aggregated - save for the most specific level - into more
general levels according to their concept hierarchies.
The averaged accuracy and AUC of random forests with
access either to a single level or a combination of all
four levels are shown in Table 5 from which we can see
that the predictive performance was improved when
including all levels of the concept hierarchies.
A random forest provided with a fused feature set,
comprising the best representations of clinical measure-
ments and clinical codes, was then built and compared
with random forests with access only to one of the data
types. The number of features of the fused feature set is
presented in Table 2 under Combination. The accuracy
and AUC for the 27 datasets are listed in Table 6.
According to a Friedman test, the observed differences
among the three random forests is significant, in terms
of both accuracy and AUC, and the post-hoc analysis
indicates that only using clinical measurements leads to
significantly worse predictive performance compared to
using clinical codes and their combination; however,
there is no significant difference between the latter two.
Table 3 Learning algorithms and their default settings.
Classifier Description Notes
DT CART decision tree minimum 1 instance per leaf
SVM Poly Support Vector
Machine
polynomial kernel of degree 3
SVM RBF Support Vector
Machine
RBF kernel, gamma = 0.0
LogReg Logistic Regression L2 regularization
kNN k nearest neighbors k = 5
AdaBoost Adaptive boosting Decision trees, 50 base estimators




RF Random forest 500 trees, inspected features =
√
n
Table 4 Comparing multiple representations of clinical
measurements.
Accuracy (rank) AUC (rank)
Mean 80.75 (2.96) 0.635 (2.74)
SD 80.23 (3.44) 0.535 (5.33)
Slope 80.54 (3.33) 0.612 (3.52)
Existence 79.25 (4.48) 0.604 (4.26)
Count 80.54 (3.63) 0.633 (2.96)
All 81.41 (2.74) 0.655 (2.19)
P-value 0.01 <0.0001
Table 5 Comparing different levels of clinical codes.
Accuracy (rank) AUC (rank)
Level 1 83.24 (3.37) 0.731 (3.74)
Level 2 84.08 (2.78) 0.742 (3.41)
Level 3 83.80 (2.93) 0.757 (2.81)
Level 4 83.93 (2.67) 0.763 (2.67)
All 84.47 (2.44) 0.763 (2.37)
P-value 0.17 0.008
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Using the most informative features
The performance of random forests using clinical mea-
surements, clinical codes and their combination after
selecting different proportions of the most informative
features according to their information gain scores are
shown in Figure 3 for accuracy and Figure 4 for AUC.
From these results we can see that applying feature
selection improved the predictive performance, albeit on
a small scale. However, even when employing feature
selection, the addition of clinical measurements fails to
improve the predictive performance compared to using
only clinical codes. An explanation for this can be
sought by investigating the outcome from different
perspectives.
From a quantitative point of view, the bar plot in
Figure 5, depicting the proportion of clinical measure-
ments and clinical codes among the selected features
indicates that, irrespective of threshold, the majority are
invariably clinical codes. From a qualitative point of
view, as shown in Figure 6, the relative informativeness
of specific representations of each data type according
to their information gain scores tells us that clinical
codes are generally more informative than clinical
measurements.
Moreover, due to the distinct nature of different
ADEs, we also present results for each individual dataset
in Figure 7 for accuracy and Figure 8 for AUC, respec-
tively. For datasets such as D642, which has the largest
number of features, feature selection clearly improves
the accuracy; while for some datasets, such as T783 and
T887, using a combination of the two data types yields
the best predictive performance.
Using various learning algorithms
Figure 9 and Figure 10 demonstrate the averaged accu-
racy and AUC, respectively, of eight additional com-
monly used learning algorithms using clinical
measurements, clinical codes and their combination
over the 27 datasets. It is clear that the random forest
algorithm outperforms the others; for most learning
Table 6 Comparing random forests using clinical measurements (M), clinical codes (C) and their combination (M+C).
Accuracy AUC
Dataset M C M+C M C M+C
D642 98.79 (3) 98.95 (2) 99.03 (1) 0.961 (3) 0.980 (2) 0.994 (1)
E273 86.98 (3) 87.51 (1) 87.51 (1) 0.691 (3) 0.706 (2) 0.741 (1)
F110 80.45 (2) 83.14 (1) 80.38 (3) 0.676 (3) 0.824 (1) 0.798 (2)
F112 68.48 (2) 72.73 (1) 66.30 (3) 0.672 (3) 0.803 (1) 0.752 (2)
F130 54.97 (3) 60.61 (1) 56.89 (2) 0.573 (3) 0.666 (1) 0.646 (2)
F132 71.33 (1) 69.47 (3) 69.47 (2) 0.558 (3) 0.686 (1) 0.616 (2)
F150 84.02 (3) 86.85 (1) 85.85 (2) 0.706 (3) 0.901 (1) 0.885 (2)
F151 84.68 (1) 82.03 (2) 82.03 (2) 0.502 (3) 0.619 (1) 0.535 (2)
F152 72.82 (3) 76.30 (1) 74.95 (2) 0.733 (3) 0.838 (1) 0.826 (2)
F190 64.78 (3) 74.58 (1) 72.88 (2) 0.608 (3) 0.805 (1) 0.782 (2)
F192 60.07 (3) 67.33 (1) 61.05 (2) 0.660 (3) 0.730 (1) 0.682 (2)
F199 90.04 (3) 91.61 (1) 90.98 (2) 0.568 (3) 0.577 (2) 0.700 (1)
G240 78.33 (3) 81.31 (1) 81.31 (1) 0.596 (3) 0.622 (2) 0.639 (1)
G251 93.34 (1) 93.29 (2) 93.29 (2) 0.328 (3) 0.719 (1) 0.523 (2)
G444 97.47 (3) 97.51 (1) 97.51 (1) 0.479 (3) 0.631 (2) 0.666 (1)
G620 93.47 (3) 94.26 (1) 94.26 (1) 0.509 (3) 0.765 (1) 0.756 (2)
I427 95.77 (3) 96.57 (2) 96.80 (1) 0.713 (3) 0.895 (1) 0.891 (2)
I952 91.92 (1) 91.63 (3) 91.84 (2) 0.517 (3) 0.552 (1) 0.542 (2)
L270 86.65 (1) 85.20 (3) 85.70 (2) 0.909 (2) 0.908 (3) 0.915 (1)
L271 89.17 (2) 89.84 (1) 89.10 (3) 0.784 (3) 0.800 (2) 0.802 (1)
O355 62.00 (3) 90.96 (2) 91.43 (1) 0.642 (3) 0.962 (1) 0.956 (2)
T782 91.02 (3) 91.90 (2) 92.09 (1) 0.695 (3) 0.712 (2) 0.717 (1)
T783 90.39 (3) 91.27 (1) 91.18 (2) 0.774 (3) 0.845 (2) 0.862 (1)
T784 60.44 (3) 68.63 (2) 68.82 (1) 0.611 (3) 0.732 (2) 0.753 (1)
T808 86.45 (3) 93.88 (1) 91.59 (2) 0.857 (3) 0.953 (2) 0.962 (1)
T886 93.57 (3) 94.05 (1) 94.05 (1) 0.629 (3) 0.655 (2) 0.656 (1)
T887 70.65 (2) 69.24 (3) 70.94 (1) 0.721 (2) 0.720 (3) 0.754 (1)
Average 81.41 (2.48) 84.47 (1.56) 83.6 (1.70) 0.655 (2.93) 0.763 (1.56) 0.754 (1.52)
P-value 0.007 < 0.0001
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algorithms, using clinical codes yields the best predictive
performance; however, for learning algorithms that are
very sensitive to high dimensionality, such as k nearest
neighbors (kNN), using measurements alone and/or
applying feature selection improve(s) the predictive per-
formance, as the number of clinical measurements is far
smaller than the number of clinical codes.
Discussion
This study investigated the use of various types of struc-
tured EHR data - clinical measurements and clinical
codes - both in isolation and in combination, to build
machine learning models for ADE detection. The results
show that using clinical codes alone, or together with
clinical measurements, leads to significantly improved
predictive performance compared to using only clinical
measurements. In addition, feature selection based on
information gain was conducted to remove relatively
less informative variables, which also enables a deeper
inspection of the informativeness of each data type and
representation.
Results analysis
We evaluated different representations of clinical mea-
surements and clinical codes using methods proposed in
[24] and [26], and slightly different results are observed
here. In the previous study that explored the possibility
of exploiting the concept hierarchies of clinical codes
[26], it was demonstrated that using only the more gen-
eral levels of the codes was sufficient to maintain the
predictive performance on a high level; in this study,
however, we observed that using all levels of the codes,
including both the general and the more specific levels,
yields the best predictive performance. A possible expla-
nation for this is that the tasks in the two studies are
different: in [26], the task was to distinguish patients
with a specific ADE from randomly selected patients
without the ADE; in this study, the task was to distin-
guish patients with a specific ADE from patients with a
similar disease to the ADE. The latter is a much more
Figure 3 Averaged accuracy from random forests using clinical
measurements (M), clinical codes (C) and their combination (M
+C) at each feature selection threshold.
Figure 4 Averaged AUC from random forests using clinical
measurements (M), clinical codes (C) and their combination (M
+C) at each feature selection threshold.
Figure 5 Proportion of clinical measurements (M) and clinical
codes (C) among selected features.
Figure 6 Relative informativeness of the 5 representations of
clinical measurements (MN: mean; SD: standard deviation; SL:
slope; YN: existence; CN: count) and 4 levels (L1 - L4) of clinical
codes based on their information gain scores. Larger area
indicates lower informativeness.
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Figure 7 Accuracy of random forest using clinical measurements (M), clinical codes (C) and their combination (M+C) at each feature
selection threshold in each dataset.
Figure 8 AUC of random forest using clinical measurements (M), clinical codes (C) and their combination (M+C) at each feature
selection threshold in each dataset.
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difficult task than the former, as the positive and nega-
tive examples are more similar in the latter. It is thus
not surprising that, in this task, more specific levels of
codes are needed to improve the predictive perfor-
mance. In the study that investigates various representa-
tions of clinical measurements [24], the model with a
combination of multiple representations outperformed
the ones with any single representation, which is consis-
tent with the observation in this study; however, the
predictive performance of models using the single repre-
sentations are inconsistent with the previous study:
Mean is the best in the former, while Count is the best
in the latter. This discrepancy might be due to slightly
different settings of the tasks in the two studies. In [24],
the task was also to distinguish patients with a specific
ADE and patients with similar diseases to the ADE, but
it is achieved by retrospectively analyzing the entire
available patient history in the EHRs, i.e., clinical events
that occurred after the target ADE were included in the
predictive models; in this study, the task was instead
designed for detecting ADEs at the point of care, which
means that only the clinical events that occurred prior
to the target ADE were allowed to be exploited in the
predictive models.
By combining clinical measurements and clinical
codes, the predictive performance does not outperform
using only clinical codes. In order to understand the
reasons for this observation, we looked at the number of
features selected from each data type and their corre-
sponding relative informativeness by ranking features
based on their information gain. In general, most of the
selected features are clinical codes, which is partly
biased as there are in fact more codes than measure-
ments in the feature set, but even when only the top
10% of features are selected, the majority of the top-
ranked features are clinical codes. Since only looking at
Figure 9 Accuracy of multiple classifiers using clinical measurements (M), clinical codes (C) and their combination (M+C) at each
feature selection threshold.
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the quantity is not fair in this case, we instead inspected
the relative informativeness, adjusted by the number of
features, between codes and measurements. It turned
out that clinical codes were consistently more informa-
tive than clinical measurements. Although by using only
clinical measurements, the predictive performance is not
worse than random guessing (average accuracy of 81.41
and AUC of 0.655), adding them to clinical codes does
not seem to be helpful in improving the predictive per-
formance compared to using codes alone. This can
partly be explained by how each tree is built in the ran-
dom forest: the algorithm selects the most informative
feature from a random subset of features as the node to
split on when building each tree. In this case, clinical
measurements are less likely to be selected as they are
inferior to clinical codes in terms of both quantity and
quality. As a result, they can almost be considered use-
less when used in conjunction with clinical codes.
Besides the random forest algorithm, we also
employed several other common learning algorithms.
Similar results are observed with AdaBoost, Bagging and
decision tree as were observed for the random forest
algorithm, while for the other learning algorithms that
are neither tree-based nor ensemble models, the results
deviate from the previous pattern. For example, logistic
regression favors the combination of clinical codes and
measurements when no feature selection is conducted; a
support vector machine with the RBF kernel using clini-
cal measurements yields better predictive performance
when only part of the features are selected; and the
k nearest neighbor algorithm always achieves better per-
formance by using clinical measurements alone. More-
over, feature selection has a different impact on these
learning algorithms, which is basically consistent with
what we know about their sensitiveness towards high
dimensionality, e.g., adding feature selection clearly
Figure 10 AUC of multiple classifiers using clinical measurements (M), clinical codes (C) and their combination (M+C) at each feature
selection threshold.
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improves the predictive performance of the k nearest
neighbor algorithm. Here, it is worth noting that among
all of the investigated learning algorithms, the random
forest classifier consistently outperforms the others for
this task, which, again, proves its robustness on handling
high dimensional data.
In addition to the averaged results over the 27 datasets,
we also presented results for each individual dataset. For
most datasets, using only clinical measurements results
in the worst performance; however, if we look at the
results for accuracy, for some datasets, such as G251,
F132 and L270, opposite results are observed; for the
AUC results, we can see that for datasets D642, E273,
F199, L270, T783, T784, T886 and T887, using a combi-
nation of clinical measurements and codes outperforms
the others. These diverse results can perhaps be
explained by the different nature of each ADE. For exam-
ple, to detect D642 (drug induced anemia), using clinical
codes only is probably not sufficient since such a diagno-
sis is often made after observing results from blood tests;
to detect ADEs starting with F (mental and behavioural
disorders), it is less likely that using clinical measure-
ments is helpful, whereas clinical notes, in this case,
might contain much more valuable information than the
structured data.
Challenges of using electronic health records for adverse
drug event detection
Although EHRs are increasingly considered as a valuable
resource for pharmocavgilance and machine learning
based methods are often favored over other methods
when analyzing large amounts of data from EHRs, it is,
by using such purely data-driven methods, difficult to
distinguish clinically relevant signals from systematic
biases in the data. Therefore, the machine learning
methods should serve primarily as tools for exploring
the massive amounts of data and testing hypotheses;
eventually, human knowledge and experience is still
necessary to evaluate the validity of the findings.
In addition to the challenges that have already been
discussed in the background section, EHR data is also
very noisy. On the one hand, the quality of the diagnosis
encoding varies according to the experience and exper-
tise of coders [38], making it difficult for data analysts
to adjust the validity and reliability of the reported
events. According to a review by the Swedish National
Board of Health and Welfare, around 20% of the
assigned primary diagnosis codes were found to be erro-
neous [39]. On the other hand, clinical codes can be
influenced by various factors, such as the knowledge
and experience of the clinicians, the amount of informa-
tion available at admission and strategic billing, render-
ing the choice of codes to report biased. In such
situations, when the codes are used to label the training
data, we should proceed with caution as they cannot
entirely be considered as a gold standard. One expensive
alternative here is to involve experts for reviewing train-
ing data and correcting incorrect labels.
Limitations and future work
One limitation of this study is that the labels in the
training data are directly extracted from the EHR data-
base without being scrutinized by clinical experts. This
could lead to findings that do not entirely reflect reality.
Moreover, both clinical codes and measurements are
represented in certain ways in this study, and hence the
results and findings are limited only to these representa-
tions. It is, for instance, conceivable that, with better
representations, clinical measurements would be as
informative as clinical codes for detecting ADEs. There-
fore, in future work, representations that can further
improve the informativeness of clinical measurements
should be explored. This study only included two types
of data, codes and measurements, from EHRs. A natural
extension would thus be to include more data types,
such as lab tests and notes.
Conclusions
We have here demonstrated how machine learning can
be employed to analyze structured data in electronic
health records for the purpose of supporting pharma-
covigilance activities such as detecting adverse drug
events. Predictive models learned from electronic health
records could be incorporated into adverse drug event
alerting systems at the point of care, primarily facilitat-
ing the correct encoding of adverse drug events, which,
in turn, would address the problem of under-reporting
of adverse drug events and lead to more reliable statis-
tics. To create high-performing predictive models, it is
essential to pay careful attention to which data to use
and how to best represent it, especially so when faced
with high-dimensional and extremely sparse data. We
have here presented a detailed study and proposed solu-
tions to the said challenges, focusing on two groups of
data: measurements and clinical codes that encode
drugs and diagnoses.
Within each data type, it is advantageous to combine
multiple representations, effectively providing a more
holistic view of the data. Across data types, providing all
representations of each data type leads to improved pre-
dictive performance for some learning algorithms, while
for the best-performing learning algorithm - random
forest - this is beneficial in certain cases only, i.e., for
specific adverse drug events. Generally speaking, clinical
codes are more informative than measurements for the
purpose of detecting adverse drug events, and it is not
necessary in general to add measurements to clinical
codes. Selecting a subset of the most informative
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features can, to some extent, lead to improved predictive
performance, even with learning algorithms that are
considered to effectively handle high-dimensional data.
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